{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACE-536&page=2", "query": { "intervention": "ACE-536", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACE-536&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-12T21:20:42.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07075406", "title": "A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-11-01", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 1, "location_summary": "Research Triangle Park, North Carolina", "locations": [ { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07075406" }, { "nct_id": "NCT05949684", "title": "ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2023-10-24", "completion_date": "2031-05-30", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 33, "location_summary": "Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949684" }, { "nct_id": "NCT07725497", "title": "A Study of Luspatercept in People With Anemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Chronic Kidney Disease" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-07-20", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725497" }, { "nct_id": "NCT05564390", "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm", "Acute Myeloid Leukemia Post Cytotoxic Therapy", "Acute Myeloid Leukemia, Myelodysplasia-Related", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Chest Radiography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Decitabine and Cedazuridine", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Gilteritinib", "type": "DRUG" }, { "name": "Liposome-encapsulated Daunorubicin-Cytarabine", "type": "DRUG" }, { "name": "Luspatercept", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olutasidenib", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2000, "start_date": "2024-06-18", "completion_date": "2029-05-15", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 336, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05564390" }, { "nct_id": "NCT01688011", "title": "Connect® Myeloid Disease Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Myelofibrosis", "Myelodysplastic Syndromes", "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2013, "start_date": "2013-12-12", "completion_date": "2024-10-18", "has_results": false, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 155, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688011" }, { "nct_id": "NCT06517875", "title": "Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2025-02-28", "completion_date": "2028-03-17", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06517875" }, { "nct_id": "NCT03194542", "title": "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Anemia" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2017-11-15", "completion_date": "2022-07-18", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03194542" }, { "nct_id": "NCT02604433", "title": "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Erythrocyte Transfusion", "Beta-Thalassemia" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2016-05-02", "completion_date": "2021-01-05", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 6, "location_summary": "Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604433" }, { "nct_id": "NCT04419649", "title": "A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Cytopenia" ], "interventions": [ { "name": "Elritercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2020-08-19", "completion_date": "2031-10-30", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 11, "location_summary": "Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04419649" }, { "nct_id": "NCT05568225", "title": "A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R" ], "interventions": [ { "name": "Etavopivat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forma Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-11-15", "completion_date": "2024-07-15", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-12T21:20:42.887Z", "location_count": 4, "location_summary": "Miami, Florida • Ocala, Florida • New York, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568225" } ] }